乐普医疗：医美业务进展超预期，“童颜针”含税收入已达1亿元左右

Core Viewpoint - Lepu Medical's aesthetic medicine business is rapidly developing, with significant revenue generation from its "童颜针" product since its launch in early August [1] Group 1: Business Performance - The "童颜针" product has generated approximately 100 million yuan in revenue since its launch, exceeding the company's expectations [1] - The product is now available in over 80% of large chain aesthetic medical institutions and around 1,500 to 2,000 small and medium-sized aesthetic medical institutions [1] Group 2: Product Features - The 220mg "童颜针" is well-received among consumers due to its excellent biocompatibility and low adverse reaction rate [1] Group 3: Future Plans - The company plans to promote the product through partnerships with platforms like Meituan and intends to launch a shareholder discount program for light aesthetic services [1] - The revenue target for the aesthetic medicine segment is set at 1 billion yuan by 2026 [1]